A Study to Assess Effects of Clarithromycin on Pharmacokinetics of JNJ-54861911 in Healthy Male Participants
Information source: Janssen Research & Development, LLC
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Healthy
Intervention: JNJ-54861911, 25 mg (Drug); Itraconazole 200 mg (Drug); Clarithromycin 500 mg (Drug)
Phase: Phase 1
Status: Completed
Sponsored by: Janssen Research & Development, LLC Official(s) and/or principal investigator(s): Janssen Research & Development, LLC Clinical Trial, Study Director, Affiliation: Janssen Research & Development, LLC
Summary
The purpose of this study is to assess the effects of strong cytochrome P450 (CYP) 3A4
inhibitors (Itraconazole and Clarithromycin), on pharmacokinetics (PK) (study of the way a
drug enters and leaves the blood and tissues over time) of single dose of JNJ-54861911 in
healthy male participants.
Clinical Details
Official title: An Open-Label, Fixed-Sequence Study to Assess Effects of Clarithromycin on the Single-Dose Pharmacokinetics of JNJ-54861911 in Healthy Male Subjects
Study design: Allocation: Non-Randomized, Endpoint Classification: Pharmacokinetics Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Maximum Observed Plasma Concentration (Cmax) of JNJ-54861911 and diaminothiazine (DIAT)Time to Reach Maximum Concentration (Tmax) of JNJ-54861911 and DIAT Time to Last Quantifiable Plasma Concentration (Tlast) of JNJ-54861911 and DIAT Area Under the Plasma Concentration-time Curve From Time Zero to Last Quantifiable Time (AUC [0-last]) of JNJ-54861911 and DIAT Area Under the Plasma Concentration-time Curve From Time Zero to Extrapolated Infinite Time (AUC [0-infinity]) of JNJ-54861911 and DIAT Area Under the Plasma Concentration-time Curve From Time Zero to Time 24 Hours (AUC [0-24]) of JNJ-54861911 and DIAT Elimination Half-Life (t1/2) of JNJ-54861911 and DIAT Elimination Rate Constant (lambda[z]) of JNJ-54861911 and DIAT
Secondary outcome: Number of Participants With Adverse Events (AEs) or Serious Adverse Events (SAEs)
Detailed description:
This is a single-center, open-label (participants and researchers are aware about the
treatment, participants are receiving), fixed-sequence study in healthy male participants
consisting of 2 sequential parts. For all participants enrolled in either part, the study
consists of 3 phases: Screening Phase (within 21 to 2 days prior to the first dose
administration on Day 1), Open-label Treatment Phase (Day 1 up to Day 12), and Follow-up
Phase (7 to 14 days after last dose administration). The maximum duration of study will be 7
weeks per participant. Study will be conducted in 2 parts to understand the relative role of
CYP3A4 and amide hydrolysis pathways in JNJ-54861911 metabolism and any potential drug-drug
interaction liability with inhibitors of these pathways. Itraconazole will be administered
in Part 1 as mixed CYP3A4 and potential amide hydrolysis inhibitor. Clarithromycin will be
administered in Part 2 as a pure CYP3A4 inhibitor. However, Part 2 of the study will only be
conducted if a relevant interaction is observed with itraconazole based on an interim review
of Part 1 data. Participants enrolled in Part 1 will receive single dose of JNJ-54861911, 25
milligram (mg) tablet orally on Day 1 and Day 9 along with itraconazole 200 mg (2*100 mg
capsule) orally once daily from Day 5 to Day 12. Participants enrolled in Part 2 will
receive single dose of JNJ-54861911, 25 mg tablet orally on Day 1 and Day 9 along with
clarithromycin 500 mg immediate release tablet orally twice daily from Day 5 to Day 12.
Blood samples will be collected pre-dose (Day 1) up to Day 13 to understand the PK
characteristics of JNJ-54861911 and diaminothiazine (DIAT, a metabolite formed after amide
hydrolysis of JNJ-54861911). In addition, a blood sample will be collected on Day - 1 from
all enrolled participants to study genotyping of CYP3A4 gene and other genetic factors that
may influence the PK, safety, and/or tolerability of JNJ-54861911 and CYP3A4 inhibitors.
Participants' safety will be monitored throughout the study.
Eligibility
Minimum age: 18 Years.
Maximum age: 55 Years.
Gender(s): Male.
Criteria:
Inclusion Criteria:
- Signed an informed consent document indicating they understand the purpose of and
procedures required for the study, and are willing to participate in the study
- Body mass index between 18 and 30 kilogram per square meter
- Must be healthy on the basis of physical examination, medical history, vital signs,
and 12-lead electrocardiogram (ECG) performed at Screening or admission (up to Day 1
predose)
- Man, who is sexually active with a woman of child-bearing potential and has not had a
vasectomy, must agree to use an adequate contraception method as deemed appropriate
by the investigator, and must also agree to not donate sperm during the study and for
90 days after receiving the study drug
- Participant must be healthy on the basis of clinical laboratory tests performed at
Screening and/or admission and as per investigator's judgment
Exclusion Criteria:
- History of or current liver or renal impairment, significant cardiac, vascular,
pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic,
psychiatric, dermatological or metabolic disturbances
- Known allergies, hypersensitivity, or intolerance to JNJ-54861911 or its excipients,
itraconazole (Part 1 only) or clarithromycin (Part 2 only)
- History of human immunodeficiency virus (HIV) antibody positive, or tests positive
for HIV at Screening
- History of drug or alcohol abuse within 6 months before Screening or positive test
result(s) for alcohol and/or drugs of abuse (including barbiturates, opiates,
cocaine, cannabinoids, amphetamines, benzodiazepines and cotinine) at Screening or
admission
- Smoking of cigarettes (or equivalent) and/or used nicotine based products within 3
months prior to study drug administration
Locations and Contacts
Merksem, Belgium
Additional Information
Starting date: July 2014
Last updated: October 13, 2014
|